granted marketing authorization for an updated formulation of Moderna’s COVID-19 mRNA vaccine Spikevax, targeting the SARS-CoV-2 variant JN.1, for individuals six months and older. See Also ...

1, for active immunization to prevent COVID-19 caused by SARS-CoV-2 in individuals six months of age and older. About Moderna Moderna is a leader in the creation of the field of mRNA medicine.

1, for active immunization to prevent COVID-19 caused by SARS-CoV-2 in individuals six months of age and older. Moderna is a leader in the creation of the field of mRNA medicine. Through the ...

Investing.com -- Moderna , Inc. (NASDAQ ... 1 and is designed for active immunization to prevent COVID-19 in individuals aged six months and older. This article was generated with the support ...

Moderna (NASDAQ:MRNA) stock drops ~5% as its Q4 2024 results show revenue beat but earnings miss expectations. Read more here ...

Moderna (MRNA), once a pandemic-era darling, has seen its stock plummet 65% over the past year, battered by fading vaccine ...

In its fourth-quarter earnings report, Moderna’s revenue was down substantially from 2023. Separately, media reports reveal ...

A member of the U.K. Parliament is calling for regulators to audit pharmaceutical companies that have made misleading ...

Moderna has reported revenue of $1bn for the fourth quarter (Q4) of 2024 - a sharp decline from the $2.8bn recorded in the ...

An image that is spreading widely online claims that Moderna had created its COVID-19 vaccine two years before the pandemic began—proof that health authorities had planned the pandemic in advance.

Moderna has been ordered to pay almost £44,000 after 12-year-olds were encouraged to join Covid vaccine trials with the ...